NCT07466420Recruiting
Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.
Study on the Efficacy of Quercetin Intake in Patients With Idiopathic Pulmonary Fibrosis and Non-Idiopathic Pulmonary Fibrosis. A Two-arm, Prospective Randomized Controlled Clinical Trial.
Source: ClinicalTrials.gov · Last updated 12 Mar 2026
Brief summary (registry, in English)
Fibrotic interstitial lung diseases (F-ILDs), including both idiopathic pulmonary fibrosis (IPF) and non-IPF, are chronic and progressive lung diseases characterized by excessive scarring of lung tissue, leading to declining lung function, respiratory failure, and high mortality, despite the currently approved antifibrotic treatment. While its exact cause remains unknown, pulmonary fibrosis is strongly linked to aging, genetic predisposition, environmental factors, and cellular senescence. Ongoing research aims to identify reliable biomarkers and develop targeted treatments to enhance patient outcomes. This randomized controlled trial will examine the effects of quercetin supplementation (500 mg/day for two 12-week cycles, with one 8-week washout periods) on telomere length, senescence-associated secretory phenotype (SASP) factors, and lung function in patients with IPF and F-ILDs. A total of 100 patients will be recruited, with half receiving quercetin (despite their standard of care therapy) and the other half receiving standard care (SOC). Primary outcomes will include changes in telomere length, SASP protein levels (IL-6, MMPs), fractional exhaled nitric oxide (FeNO), spirometry (FVC decline), and oscillometry measurements. Additionally, quality of life will be assessed using the L-IPF Questionnaire. This study aims to explore quercetin's potential to reduce fibrosis, decrease inflammation, and improve lung function in F-ILDs, offering new insights into potential novel strategies for F-ILD management.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 2 Feb 2026
- Start date
- 26 Jan 2026
- Primary completion date
- 31 Jan 2028
- Lead sponsor
- Katerina M. Antoniou
- Diseases
- Idiopathic pulmonary fibrosis
- NCT number
- NCT07466420
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 26 Jan 2026 to the primary completion date, 31 Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Subjects with a result of FeNO\>25 ppb will be excluded from the study to ensure that no other pulmonary diseases, such as asthma, are present.
Other
- Patients who do not initiate quercetin within the first week after their baseline visit.
Who the study is looking for
- Patients with an established diagnosis of IPF and Fibrotic ILD and will be eligible to participate in the study.
- The use of the approved standard of care antifibrotic therapy, either nintedanib or pirfenidone, and immunosuppressive therapy will be allowed as standard of care.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Respiratory Department, University Hospital of Heraklion, School of Medicine, University of Crete Coordinator of this site? Confirm its status | Heraklion | Greece | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.